EN DE
Check 35,000+ stocks against 26 valuation models and 37 quality factors
Data-driven stock valuation

Pluristem (PSTI) fair value: what the stock is really worth

As of Oct 9, 2026: fair value of Pluristem ILS 0.96, price ILS 3.01, upside -68.1%, quality 19 out of 100. Calculated from audited financials with 26 valuation models and 37 quality factors, updated daily.

  1. Fair value above price? No
  2. Good quality? No
  3. Add to watchlist

Healthcare · Il · ISIN US72940R3003

P Thin data Oct 3, 2026

Pluristem

PSTI · TA

Weakest SetupStrongly overvalued and low quality.

Fair value 0.9600 ILA · Strongly overvalued (−68.1%)
Quality 19/100
Weak Growth (revenue 5y −42.9 %/yr in ILA)
Negative free cash flow
Trails peers (1/7)
Narrow moat 5/100
Thin data
Watch Pluristem for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

112.80 ILA 3.00 ILA Fair Value 0.9600 ILA May 2021 Oct 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Oct 3, 2026.

How to read this chart

60‑month range 3.00 ILA – 112.80 ILA · fair‑value band 0.6300 ILA – 1.20 ILA · the 3.01 ILA price screens above the 0.9600 ILA fair value. Dashed = 300-day average. As of Oct 3, 2026.

Follow Pluristem in your weekly email

Every Wednesday you see whether Pluristem is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions.

Show more

Pluri Inc., a biotechnology company, focuses on the development of placenta-based cell therapy product candidates for the treatment of multiple inflammatory, muscle injuries, and hematologic conditions. The company develops placental expanded (PLX) based cell therapy products, including PLX-PAD that is in Phase III clinical trials for the muscle recovery after surgery for hip fracture; in Phase II clinical trails for the treatment of acute respiratory distress syndrome associated with COVID-19; and in Phase I/II clinical trial for treatment of steroid-refractory graft versus host disease. It also develops PLX-R18 for incomplete hematopoietic recovery following hematopoietic cell transplantation, as well as a solution for the treatment of acute radiation syndrome. The company was formerly known as Pluristem Therapeutics Inc. and changed its name to Pluri Inc. in July 2022. Pluri Inc. was incorporated in 2001 and is based in Haifa, Israel.

Stock analysis

Pluristem (PSTI) currently trades at 3.01 ILA, while our model-based Fair Value estimate is 0.9600 ILA, 68.1% below the price, so the stock looks overvalued today.

Show more

Valuation

How firm this estimate is: it rests on 1 models at a data quality of 88/100, which puts the evidence level at low.

Scenario range: 0.6300 ILA (bear) to 1.20 ILA (bull), the price of 3.01 ILA sits above it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 19/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue is shrinking: the last year, the last three and the last five years are all negative.

Pluristem reported revenue of 0 ILA in FY2021 versus 0 ILA in FY2017. Reported net income was −49.9M ILA in FY2021.

Key figures

Market cap 117M ILA · EPS (TTM) −1.46 ILA · Return on equity −86.6% · Return on assets (EBIT) −74.8% · Operating margin −20,213% · Revenue (TTM) 234K ILA · Revenue growth (YoY) −54.0% · Free cash flow −31.3M ILA.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 22 out of 100 (medium confidence).

What moves the price

The share trades about 80% below its 52-week high and at its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −33% fair-value upside, at −68%, PSTI screens richer than that median.

Fair Value models

Bear 0.6300 ILA Fair Value 0.9600 ILA Bull 1.20 ILA
Price 3.01 ILA · Upside -68.1%
Model ⓘEach model values the company its own way (discounted cash flow, earnings, assets, dividends). The fair value above is their evidence-weighted blend, not the output of a single model. Bear ⓘBear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull ⓘBull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. If a model's bull case is above four times its base value, the table shows that limit with a > sign (like the overall Bull above): beyond it no assumption holds. Evidence ⓘEvidence = how well-backed THIS model's estimate is for this stock (0–100): how complete and reliable its input data are, and how well the model fits the company. The final Fair Value is an evidence-weighted blend, so better-evidenced models count more. Green ≥70, amber 50–69, grey below 50.
Highest evidence
NCAV (Graham) 0.8800 ILA 1.18 ILA 1.77 ILA 51
All 1 models by family
Asset-Based
NCAV (Graham) 0.8800 ILA 1.18 ILA 1.77 ILA 51

Open the full fair value analysis →

Quality Score breakdown

Overall quality 19/100

Of which business quality 19 · Market factors (momentum, volatility) 0

Profitability 0
Margins and returns on capital today
Quality Growth 17
Are margins and returns improving?
Cashflow 8
Earnings quality: real cash, not paper profit
Fin. Strength 73
Balance sheet, leverage, solvency risk
Investment 0
Disciplined investing over empire-building
Low Volatility 0
Calm price path (market factor)
Momentum 0
Price trend over the last 3–12 months (market factor)
52W Momentum 0
Distance to the 52-week high (market factor)
Net Issuance 0
Share count: buybacks or dilution?

Open the full quality analysis →

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 0/100
Revenue is shrinking: the last year, the last three and the last five years are all negative.
Revenue growth 1 year
−57.4%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−42.9%
Revenue growth 6 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−37.3%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−6,666.8% (2015) → −128,156.5% (2020)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2021 is a loss year, no rate is defined from a loss
not computed

PSTI screens overvalued: fair value 68% below the price. Compare with MEDIPOST Co →

Compare Pluristem with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its sector: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median. (Industry “Biotechnology & Medical Research” was too small, so the broader sector is used.)Health Care · 2375 stocks

Beats the sector median on 1/6 measures
Overall it trails its sector peers.
Valuation
Quality Score 19 · Bottom 25%
Fair Value upside −68.1% · Bottom 25%
Profitability
Return on assets −37.4% · Bottom 25%
Growth and dividend
Revenue growth −54.0% · Bottom 25%
Dividend yield (TTM) 0.0% · Bottom 25%

Valuation Multiplesvs Health Care median · lower = cheaper

P/B 0.67× · Cheapest 25%

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Biotechnology & Medical Research stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Purple Biotech Ltd KTOV 0.0100 ILA 0.0160 ILA +60% vs PSTI
Cell Biotech Co 049960 15,390 KRW 15,078 KRW −2% vs PSTI
AbbVie Inc ABBV $265.76 $259.62 −2% vs PSTI
Biotoxtech Co 086040 2,275 KRW 1,916 KRW −16% vs PSTI
Johnson & Johnson, JNJ $252.93 $168.85 −33% vs PSTI
Eli Lilly and Company LLY $1,143 $749.08 −34% vs PSTI
MEDIPOST Co 078160 9,710 KRW 4,207 KRW −57% vs PSTI
Bioneer Corporation 064550 8,520 KRW 3,547 KRW −58% vs PSTI
Panagene Inc 046210 1,230 KRW 480.36 KRW −61% vs PSTI
Macrogen, Inc 038290 12,680 KRW 4,457 KRW −65% vs PSTI

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names ⭐ Top Rated 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Calculator with industry benchmark Peter Lynch Fair Value Formula &…Calculator with industry benchmark
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Pluristem · Fair Value
0.9600 ILA −68%Fair Value
Calculator →

Cite: Fair Value Calculator (2026). "Pluristem Fair Value". https://www.fairvalue-calculator.com/stock/PSTI

Frequently asked questions

Is Pluristem (PSTI) overvalued or undervalued?
As of Oct 3, 2026, our model estimates a fair value of 0.9600 ILA versus a price of 3.01 ILA, about −68% upside (overvalued).
What is the fair value of PSTI?
Our model-based fair value for Pluristem is 0.9600 ILA (as of Oct 3, 2026), built from audited fundamentals. The current price: 3.01 ILA.
What is the quality score of PSTI?
Pluristem has a Quality Score of 19/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for Pluristem (PSTI)?
Our model-based price target is the fair value of 0.9600 ILA (as of Oct 3, 2026) from 1 valuation models. Cautious scenario 0.6300 ILA, optimistic scenario 1.20 ILA. It is a calculation from audited fundamentals, not an analyst target.
What is the Pluristem stock forecast for 2026?
Our models put fair value at 0.9600 ILA, about −68% upside versus a price of 3.01 ILA (overvalued). Cautious scenario 0.6300 ILA, optimistic scenario 1.20 ILA. The calculation is refreshed regularly with new filings.
What is the revenue of Pluristem (PSTI)?
Pluristem reported trailing-twelve-month revenue of about 234K ILS (latest available figure, as of Oct 3, 2026).
What is the intrinsic value of Pluristem (PSTI)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For Pluristem it is 0.9600 ILA per share (as of Oct 3, 2026), against a price of 3.01 ILA. It is the blended result of 1 valuation models (cash flow, earnings, asset, dividend).
Is Pluristem stock overvalued or undervalued in 2026?
As of Oct 3, 2026, PSTI trades above its calculated fair value: price 3.01 ILA, fair value 0.9600 ILA, a gap of about −68% (overvalued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of PSTI?
No. The price is what the market pays today (3.01 ILA); the fair value is what the company's own numbers justify (0.9600 ILA). For Pluristem the two are 2.05 ILA per share apart. That gap is exactly why we show both numbers side by side.
How much is Pluristem worth?
The market values Pluristem at about 117M ILA (market capitalisation, as of Oct 3, 2026). Per share that is 3.01 ILA; our models calculate a fair value of 0.9600 ILA per share.
What do the bullish and bearish scenarios say about PSTI?
Our models span a range for Pluristem: cautious scenario 0.6300 ILA, base 0.9600 ILA, optimistic 1.20 ILA per share (as of Oct 3, 2026, price 3.01 ILA). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of Pluristem (PSTI)?
Balance-sheet figures for Pluristem (as of Oct 3, 2026): return on equity −86.6%. They feed the Quality Score of 19/100, which measures business quality independently of the share price.
How far is PSTI from its 52-week high?
Pluristem trades at 3.01 ILA, about 80% below its 52-week high of 14.97 ILA and at the low of 3.00 ILA (as of Oct 9, 2026). Distance from the high says nothing about value: that is what the fair value of 0.9600 ILA is for.
Which stocks are comparable to Pluristem?
From the same area (Healthcare) we also value MEDIPOST Co, Bioneer Corporation, Macrogen, Inc, Cell Biotech Co, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is Pluristem stock attractive at the current price?
The data as of Oct 3, 2026: price 3.01 ILA, calculated fair value 0.9600 ILA (−68%), Quality Score 19/100, from 1 models. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
How is the fair value of PSTI calculated?
We run Pluristem through 1 models from four families: discounted cash flow, earnings models, asset and balance-sheet models, and dividend models. Every model gets the same audited fundamentals; the result is the weighted average of 0.9600 ILA, with the spread shown as a cautious and an optimistic scenario.
Is it still worth investing in stocks now?
The global stock market currently sits 14.9 % above its aggregate fair value. Pluristem itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of Pluristem (PSTI)?
The closing price on Oct 9, 2026 was 3.01 ILA. Our model-based fair value is 0.9600 ILA, about −68% upside (overvalued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with Pluristem right now?
The price sits above even our optimistic bull case (1.20 ILA). The favourable scenario is already priced in. Weak quality (19/100) and above fair value at the same time, the margin of safety is missing on both counts. The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution. A fairly wide model range (0.6300 ILA to 1.20 ILA) leaves room in how you read the outcome.

Key figures of Pluristem

How large is the market capitalisation of Pluristem (PSTI)?
The market capitalisation of Pluristem is 117M ILA. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What are the earnings per share of Pluristem (PSTI)?
Earnings per share at Pluristem are −1.46 ILA. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of Pluristem (PSTI)?
The return on equity (ROE) of Pluristem is −86.6% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of Pluristem (PSTI)?
On an EBIT basis the return on assets of Pluristem is −74.8% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of Pluristem (PSTI)?
The operating margin of Pluristem is −20,213% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at Pluristem (PSTI)?
Revenue at Pluristem is growing −54.0% versus a year earlier. How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does Pluristem (PSTI) generate?
The free cash flow of Pluristem is −31.3M ILA (fiscal year 2021). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
Free · no account needed

Watch Pluristem in the live analysis

One click puts Pluristem on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 35,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.